title: [Verification of CTL assay and DTH used in monitoring of peptide-pulsed dendritic cell therapy].
abstract: CTL assay and DTH used in monitoring cases of peptide-pulsed DC subcutaneous vaccination therapy (with high value of serum CEA by HLA2402) using CEA652 (9) that carried out at our facilities were verified. One out of 10 cases (10%) was SD, and 3 out of 10 cases were the induction of the CTL precursor observed for CTL assay in the peripheral blood of patients after the completion of 1 cycle (administered three times). In 2 cases, positive conversion was observed for DTH reaction. For the SD case, both CTL induction and positive conversion for DTH was observed. A reduction of the CEA value was observed in 3 patients among the 9 cases of PD. While the usefulness of CTL assay and DTH in monitoring cannot be determined solely by the verification at this time, the possibility of observing many clinical reactions could be shown for CEA652 (9) in cases where positive conversion was observed.
authors.affiliation: Dept. of Surgery II, Fukushima Medical University.
authors.forename: Manabu
authors.initials: M
authors.lastname: Iwadate
authors.forename: Masashi
authors.initials: M
authors.lastname: Kanazawa
authors.forename: Yu
authors.initials: Y
authors.lastname: Satou
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Monma
authors.forename: Motoki
authors.initials: M
authors.lastname: Sassa
authors.forename: Satoshi
authors.initials: S
authors.lastname: Suzuki
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Endoh
authors.forename: Izumi
authors.initials: I
authors.lastname: Nakamura
authors.forename: Shinji
authors.initials: S
authors.lastname: Ohki
authors.forename: Kouji
authors.initials: K
authors.lastname: Sekikawa
authors.forename: Seiichi
authors.initials: S
authors.lastname: Takenoshita
authors.forename: Tadayuki
authors.initials: T
authors.lastname: Takagi
authors.forename: Atsushi
authors.initials: A
authors.lastname: Irisawa
authors.forename: Hiromasa
authors.initials: H
authors.lastname: Oohira
authors.forename: Takashi
authors.initials: T
authors.lastname: Ogata
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Ohto
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002272:Carcinoembryonic Antigen / Q000097:blood*; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology* / Q000637:transplantation*; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology*; D007167:Immunotherapy; D007279:Injections, Subcutaneous; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000276:immunology / Q000473:pathology / Q000628:therapy; D010446:Peptide Fragments / Q000276:immunology*; D015203:Reproducibility of Results; D012882:Skin Tests; D013602:T-Lymphocytes, Cytotoxic / Q000166:cytology / Q000276:immunology*
chemical_list: D002272:Carcinoembryonic Antigen; D010446:Peptide Fragments